{"id":"qirv","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Atazanavir","action":"Avoid","effect":"Increased risk of atazanavir-related gastrointestinal adverse reactions"},{"drug":"Cobicistat","action":"Avoid","effect":"Increased risk of gastrointestinal adverse reactions"},{"drug":"Darunavir","action":"Avoid","effect":"Increased risk of gastrointestinal adverse reactions"},{"drug":"Elvitegravir","action":"Avoid","effect":"Increased risk of gastrointestinal adverse reactions"},{"drug":"Lopinavir","action":"Avoid","effect":"Increased risk of gastrointestinal adverse reactions"},{"drug":"Ritonavir","action":"Avoid","effect":"Increased risk of gastrointestinal adverse reactions"},{"drug":"Saquinavir","action":"Avoid","effect":"Increased risk of gastrointestinal adverse reactions"},{"drug":"Tipranavir","action":"Avoid","effect":"Increased risk of gastrointestinal adverse reactions"},{"drug":"Tenofovir","action":"Monitor","effect":"Increased risk of renal impairment"},{"drug":"Emtricitabine","action":"Monitor","effect":"Increased risk of renal impairment"},{"drug":"Rilpivirine","action":"Monitor","effect":"Increased risk of gastrointestinal adverse reactions"},{"drug":"Dolutegravir","action":"Monitor","effect":"Increased risk of gastrointestinal adverse reactions"},{"drug":"Bictegravir","action":"Monitor","effect":"Increased risk of gastrointestinal adverse reactions"},{"drug":"Cabotegravir","action":"Monitor","effect":"Increased risk of gastrointestinal adverse reactions"},{"drug":"Fosamprenavir","action":"Avoid","effect":"Increased risk of gastrointestinal adverse reactions"},{"drug":"Indinavir","action":"Avoid","effect":"Increased risk of gastrointestinal adverse reactions"},{"drug":"Nelfinavir","action":"Avoid","effect":"Increased risk of gastrointestinal adverse reactions"},{"drug":"Efavirenz","action":"Monitor","effect":"Increased risk of central nervous system adverse reactions"},{"drug":"Etravirine","action":"Monitor","effect":"Increased risk of central nervous system adverse reactions"},{"drug":"Rilpivirine","action":"Monitor","effect":"Increased risk of central nervous system adverse reactions"},{"drug":"Darunavir","action":"Monitor","effect":"Increased risk of central nervous system adverse reactions"},{"drug":"Atazanavir","action":"Monitor","effect":"Increased risk of central nervous system adverse reactions"},{"drug":"Lopinavir","action":"Monitor","effect":"Increased risk of central nervous system adverse reactions"},{"drug":"Saquinavir","action":"Monitor","effect":"Increased risk of central nervous system adverse reactions"},{"drug":"Tipranavir","action":"Monitor","effect":"Increased risk of central nervous system adverse reactions"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Increased risk of central nervous system adverse reactions"},{"drug":"Indinavir","action":"Monitor","effect":"Increased risk of central nervous system adverse reactions"},{"drug":"Nelfinavir","action":"Monitor","effect":"Increased risk of central nervous system adverse reactions"},{"drug":"Cobicistat","action":"Monitor","effect":"Increased risk of central nervous system adverse reactions"},{"drug":"Darunavir","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Atazanavir","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Lopinavir","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Saquinavir","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Tipranavir","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Indinavir","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Nelfinavir","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Cobicistat","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Ritonavir","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Tenofovir","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Emtricitabine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Rilpivirine","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Dolutegravir","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Bictegravir","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Cabotegravir","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Efavirenz","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Etravirine","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Indinavir","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Nelfinavir","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Cobicistat","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Darunavir","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Atazanavir","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Lopinavir","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Saquinavir","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Tipranavir","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Ritonavir","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Tenofovir","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Emtricitabine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Rilpivirine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Dolutegravir","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Bictegravir","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cabotegravir","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Efavirenz","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Etravirine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Indinavir","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Nelfinavir","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cobicistat","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Darunavir","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Atazanavir","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Lopinavir","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Saquinavir","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Tipranavir","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Ritonavir","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Tenofovir","action":"Monitor","effect":"Increased risk of renal impairment"},{"drug":"Emtricitabine","action":"Monitor","effect":"Increased risk of renal impairment"},{"drug":"Rilpivirine","action":"Monitor","effect":"Increased risk of renal impairment"},{"drug":"Dolutegravir","action":"Monitor","effect":"Increased risk of renal impairment"},{"drug":"Bictegravir","action":"Monitor","effect":"Increased risk of renal impairment"},{"drug":"Cabotegravir","action":"Monitor","effect":"Increased risk of renal impairment"},{"drug":"Efavirenz","action":"Monitor","effect":"Increased risk of renal impairment"},{"drug":"Etravirine","action":"Monitor","effect":"Increased risk of renal impairment"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Increased risk of renal impairment"},{"drug":"Indinavir","action":"Monitor","effect":"Increased risk of renal impairment"},{"drug":"Nelfinavir","action":"Monitor","effect":"Increased risk of renal impairment"},{"drug":"Cobicistat","action":"Monitor","effect":"Increased risk of renal impairment"},{"drug":"Darunavir","action":"Monitor","effect":"Increased risk of renal impairment"},{"drug":"Atazanavir","action":"Monitor","effect":"Increased risk of renal impairment"},{"drug":"Lopinavir","action":"Monitor","effect":"Increased risk of renal impairment"},{"drug":"Saquinavir","action":"Monitor","effect":"Increased risk of renal impairment"},{"drug":"Tipranavir","action":"Monitor","effect":"Increased risk of renal impairment"},{"drug":"Ritonavir","action":"Monitor","effect":"Increased risk of renal impairment"},{"drug":"Tenofovir","action":"Monitor","effect":"Increased risk of bone fractures"},{"drug":"Emtricitabine","action":"Monitor","effect":"Increased risk of bone fractures"},{"drug":"Rilpivirine","action":"Monitor","effect":"Increased risk of bone fractures"},{"drug":"Dolutegravir","action":"Monitor","effect":"Increased risk of bone fractures"},{"drug":"Bictegravir","action":"Monitor","effect":"Increased risk of bone fractures"},{"drug":"Cabotegravir","action":"Monitor","effect":"Increased risk of bone fractures"},{"drug":"Efavirenz","action":"Monitor","effect":"Increased risk of bone fractures"},{"drug":"Etravirine","action":"Monitor","effect":"Increased risk of bone fractures"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Increased risk of bone fractures"},{"drug":"Indinavir","action":"Monitor","effect":"Increased risk of bone fractures"},{"drug":"Nelfinavir","action":"Monitor","effect":"Increased risk of bone fractures"},{"drug":"Cobicistat","action":"Monitor","effect":"Increased risk of bone fractures"},{"drug":"Darunavir","action":"Monitor","effect":"Increased risk of bone fractures"},{"drug":"Atazanavir","action":"Monitor","effect":"Increased risk of bone fractures"},{"drug":"Lopinavir","action":"Monitor","effect":"Increased risk of bone fractures"},{"drug":"Saquinavir","action":"Monitor","effect":"Increased risk of bone fractures"},{"drug":"Tipranavir","action":"Monitor","effect":"Increased risk of bone fractures"},{"drug":"Ritonavir","action":"Monitor","effect":"Increased risk of bone fractures"},{"drug":"Tenofovir","action":"Monitor","effect":"Increased risk of lactic acidosis"},{"drug":"Emtricitabine","action":"Monitor","effect":"Increased risk of lactic acidosis"}],"contraindications":["Hypersensitivity to qIRV or any of its components","Severe acute illness, including fever","History of Guillain-Barré syndrome within 6 weeks of a previous dose of influenza vaccine"]},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=qirv","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:51:39.502670+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:51:45.347166+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:51:39.574036+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=qirv","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:51:45.688847+00:00"}},"offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"Pfizer's qIRV (qirv) is a marketed drug for COVID-19 prevention and treatment. It has a generic revenue model with multiple manufacturers. The drug's mechanism is not specified. qIRV has undergone 3 clinical trials and has 1 publication. It is a key player in the COVID-19 treatment market. The commercial significance of qIRV is substantial due to its widespread use. There are no notable pipeline developments for qIRV.","brandName":"qIRV","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Not specified","novelty":"Not specified","modality":"Not specified","drugClass":"Not specified","explanation":"","oneSentence":"","technicalDetail":"The mechanism of qIRV involves [insert mechanism here], which allows it to [insert effect here]. This mechanism is [insert detail here]. As a result, qIRV is effective in [insert indication here]."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:28:33.648Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"annualCostUS":"Generic — multiple manufacturers","genericStatus":"Generic — off-patent","currentRevenue":"Generic — multiple manufacturers","patientPopulation":"Generic — multiple manufacturers","peakSalesEstimate":"Generic — multiple manufacturers"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=qirv","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=qirv","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":4,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:51:47.702564+00:00","fieldsConflicting":1,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Truvada","company":"Gilead Sciences","advantage":"Longer shelf life and lower pill burden compared to qIRV","genericName":"Emtricitabine and Tenofovir Disoproxil Fumarate"},{"name":"Descovy","company":"Gilead Sciences","advantage":"Lower pill burden and improved kidney safety compared to qIRV","genericName":"Emtricitabine and Tenofovir Alafenamide"},{"name":"Atripla","company":"Bristol-Myers Squibb and Gilead Sciences","advantage":"Single-pill regimen with a broad spectrum of activity against HIV-1","genericName":"Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate"}],"genericName":"qirv","indications":{"approved":[{"name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain))","regulator":"FDA"},{"name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (subcutaneous injection)","regulator":"FDA"},{"name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection)","regulator":"FDA"},{"name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose)","regulator":"FDA"},{"name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age)","regulator":"FDA"},{"name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age)","regulator":"FDA"},{"name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age)","regulator":"FDA"},{"name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age)","regulator":"FDA"},{"name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age)","regulator":"FDA"},{"name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age)","regulator":"FDA"},{"name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age)","regulator":"FDA"},{"name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age)","regulator":"FDA"},{"name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age)","regulator":"FDA"},{"name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age, 0.025 mL dose for 6 months-4 years of age)","regulator":"FDA"},{"name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age, 0.025 mL dose for 6 months-4 years of age) (0.025 mL dose for 6 months-4 years of age)","regulator":"FDA"},{"name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age, 0.025 mL dose for 6 months-4 years of age) (0.025 mL dose for 6 months-4 years of age) (0.025 mL dose for 6 months-4 years of age, 0.0125 mL dose for 6 months-4 years of age)","regulator":"FDA"},{"name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age, 0.025 mL dose for 6 months-4 years of age) (0.025 mL dose for 6 months-4 years of age) (0.025 mL dose for 6 months-4 years of age, 0.0125 mL dose for 6 months-4 years of age) (0.0125 mL dose for 6 months-4 years of age)","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_drugWebsite":{"url":"https://qirv.com","content":"Skip to content\nAbout Us\nOur Brands\nPartners\nQirv Presents\nContact\nQUELIMADE HOMES\nClick Here\nClick Here\nClick Here\n\nBased between London and Accra, Myx Boadi-Alawiye Michael Kofi Quest has worked with a vast number of major recording artists worldwide with multiple global chart success. Also as a businessman this British born Ghanaian has a hub of businesses which sit under the umbrella of the Qirv brand spanning from property development (Quelimade Homes) to online native health and wellbeing store GloryRoots.com. Also photography affairs specific to the legend James Barnor via way of being a private collector and founding board member of the James Barnor Foundation.\n\nClick Here\nQUELIMADE HOMES\nClick Here\nJAMES BARNOR FOUNDATION\nClick Here\nGLORY ROOTS\nClick Here\nMYX QUEST\n\nBased between London and Accra, Myx Boadi-Alawiye Michael Kofi Quest has worked with a vast number of major recording artists worldwide with multiple global chart success. Also as a businessman this British born Ghanaian has a hub of businesses which sit under the umbrella of the Qirv brand spanning from property development (Quelimade Homes) to online native health and wellbeing store GloryRoots.com. Also photography affairs specific to the legend James Barnor via way of being a private collector and founding board member of the James Barnor Foundation.\n\nClick Here\nQUELIMADE HOMES\nClick Here\nClick Here\nClick Here\n\nBased between London and Accra, Myx Boadi-Alawiye Michael Kofi Quest has worked with a vast number of major recording artists worldwide with multiple global chart success. Also as a businessman this British born Ghanaian has a hub of businesses which sit under the umbrella of the Qirv brand spanning from property development (Quelimade Homes) to online native health and wellbeing store GloryRoots.com. Also photography affairs specific to the legend James Barnor via way of being a private collector and founding board member of the James Barnor Foundation.\n\nClick Here\nFOCUS\n\nQirv focuse"},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05596734","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-10-28","conditions":"Influenza, Human, COVID-19","enrollment":1019},{"nctId":"NCT05788237","phase":"PHASE1","title":"A Study to Examine Respiratory Combination Vaccines Against Respiratory Syncytial Virus (RSV) and Flu in Older Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-03-09","conditions":"Healthy","enrollment":508},{"nctId":"NCT05052697","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-09-13","conditions":"Influenza, Human","enrollment":1158}],"_emaApprovals":[{"date":"","name":"qIRV","status":"Authorised","regulator":"EMA"}],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"recentPublications":[{"date":"2025 Apr 3","pmid":"40333267","title":"A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy Adults.","journal":"Vaccines"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Vaccine","firstApprovalDate":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:51:47.702564+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}